Cargando…

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetoclax. We in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avsec, Damjan, Škrlj Miklavčič, Marja, Burnik, Tilen, Kandušer, Maša, Bizjak, Maruša, Podgornik, Helena, Mlinarič-Raščan, Irena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547871/ https://www.ncbi.nlm.nih.gov/pubmed/36209148 http://dx.doi.org/10.1038/s41419-022-05287-6

Ejemplares similares

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
por: Avsec, Damjan, et al.
Publicado: (2021)

The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies
por: Markovič, Tijana, et al.
Publicado: (2022)

A Putative Serine Protease is Required to Initiate the RIPK3-MLKL—Mediated Necroptotic Death Pathway in Neutrophils
por: Wang, Xiaoliang, et al.
Publicado: (2021)

Pipette tip with integrated electrodes for gene electrotransfer of cells in suspension: a feasibility study in CHO cells
por: Rebersek, Matej, et al.
Publicado: (2011)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy
por: Nabergoj, Sanja, et al.
Publicado: (2018)

Folate Insufficiency Due to MTHFR Deficiency Is Bypassed by 5-Methyltetrahydrofolate
por: Vidmar Golja, Maša, et al.
Publicado: (2020)

Pharmacogenetics of thiopurine therapy: from thiopurine S-methyltransferase to S-adenosylmethionine
por: Mlinarič-Raščan, Irena, et al.
Publicado: (2009)

Cell electrofusion using nanosecond electric pulses
por: Rems, Lea, et al.
Publicado: (2013)

A Double-Edged Kinase Lyn: A Positive and Negative Regulator for Antigen Receptor–mediated Signals
por: Nishizumi, Hirofumi, et al.
Publicado: (1998)

PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy
por: Smid, Alenka, et al.
Publicado: (2016)

A Common Polymorphism in the MTHFD1 Gene Is a Modulator of Risk of Congenital Heart Disease
por: Karas Kuželički, Nataša, et al.
Publicado: (2022)

Electroporator with automatic change of electric field direction improves gene electrotransfer in-vitro
por: Reberšek, Matej, et al.
Publicado: (2007)

Association of ITPA Genotype with Event-Free Survival and Relapse Rates in Children with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
por: Smid, Alenka, et al.
Publicado: (2014)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

New Insights into the Mechanisms of Gene Electrotransfer – Experimental and Theoretical Analysis
por: Pavlin, Mojca, et al.
Publicado: (2015)

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors
por: Besse, Andrej, et al.
Publicado: (2022)

A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering
por: Murn, Jernej, et al.
Publicado: (2009)

Selective Cytotoxicity of Amidinopiperidine Based Compounds Towards Burkitt’s Lymphoma Cells Involves Proteasome Inhibition
por: Gobec, Martina, et al.
Publicado: (2012)

Discovery of Novel Small-Molecule Compounds with Selective Cytotoxicity for Burkitt’s Lymphoma Cells Using 3D Ligand-Based Virtual Screening
por: Gobec, Martina, et al.
Publicado: (2014)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis
por: Grželj, Jasna, et al.
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Regulation of Immunoproteasome Function in the Lung
por: Keller, Ilona E., et al.
Publicado: (2015)

Dysfunctional immunoproteasomes in autoinflammatory diseases
por: Arimochi, Hideki, et al.
Publicado: (2016)

On the Role of the Immunoproteasome in Protein Homeostasis
por: Basler, Michael, et al.
Publicado: (2021)

The Function of Immunoproteasomes—An Immunologists’ Perspective
por: van den Eshof, Bart L., et al.
Publicado: (2021)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

Blood Nanoparticles – Influence on Extracellular Vesicle Isolation and Characterization
por: Holcar, Marija, et al.
Publicado: (2021)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

A Comprehensive Genetic Analysis of Slovenian Families with Multiple Cases of Orofacial Clefts Reveals Novel Variants in the Genes IRF6, GRHL3, and TBX22
por: Slavec, Lara, et al.
Publicado: (2023)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
por: Przedborski, Michelle, et al.
Publicado: (2022)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q65o2nlvc761m0f9v7j80m147p